natgillin/translations-raw huggingface dataset:
With said cold rolling step the strip thickness is brought to the desired final value and thereafter the strip is subjected to either an endless or batch annealing and skin-pass with return to the same cold rolling mill. 
Pomoću navedenog koraka hladnog valjanja debljina trake je dovedena do željene krajnje vrijednosti nakon čega je traka podvrgnuta bilo beskonačnom ili grupnom žarenju i polirajućem valjanju sa povratkom na istu hladnu valjaonicu.
3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for use according to claim 1, wherein the mantle cell lymphoma is relapsed, refractory or resistant to conventional therapy. 
-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što limfom stanica plašta je recidivirao, refraktaran ili otporan na konvencionalnu terapiju.
The combination as defined in claim 4 wherein the antidiabetic agent is at least one agent selected from the group consisting of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, isaglitazone, repaglinide, nateglinide, muraglitizar and peliglitazar. 
Kombinacija prema patentnom zahtjevu 4, naznačena time što je antidijabetično sredstvo najmanje jedno sredstvo izabrano iz grupe koju čine metformin, gliburid, glimepirid, glipirid, glipizid, klorpropamid, gliklazid, akarboza, miglitol, pioglitazon, troglitazon, rosiglitazon, inzulin, isaglitazon, repaglinid, nateglinid, muraglitizar i peliglitazar.
To further illustrate without limiting the invention an embodiment of R3 is C1-10-alk(en/yn)yl; 
Spoj prema patentnom zahtjevu 2, naznačen time što je R3 jednako C,_.,0-alk(en/in)il.
a)providing at least one aqueous calcium carbonate containing mineral slurry; 
osiguravanja barem jedne vodene suspenzije koja sadrži kalcijev karbonat koji sadrži mineral; b)
A system according to any one of claims 2-11, wherein the thickness of the flange-like rim is greater at the location where the ridges are present than at a location adjacent thereto. 
Sistem prema bilo kojem od patentnih zahtjeva 2-7, naznačen time da je debljina (HF) ruba (20) u obliku prirubnice veća na mjestu gdje se nalaze ispusti (28.i) nego na njemu susjednom mjestu.
After stirring at 45 °C for 1 hour, the reaction mixture is filtered to remove any undissolved material and is evaporated to dryness. 
Nakon miješanje 1 sat pri 45"C, reakcijsku smjesu se profiltrira da se odstrani sav neotopljen materijal i ispari se do suhog.
about 0.5% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 70.5% metformin hydrochloride; about 5.5% hydroxypropyl cellulose; about 20.5% microcrystalline cellulose; about 5% sodium starch glycolate; and about 1% magnesium stearate; 
(E) _0.5% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 70.5% metformin hidroklorida; 5.5% hidroksipropil celuloze; 20.5% mikrokristalne celuloze; 5% natrijevog škrob glikolata; i 1% magnezijevog stearata;
In one embodiment of the present invention, there is a gap between the reaction chamber base and the heater, and said gap is ranging from about 0.2 mm to about 0.7 mm. 
Mikročip (10) prema zahtjevu 1, pri čemu se između reakcijske komore (11) baze 1 grijača (12) nalazi praznina veličine od 0,2 mm do 0,7 mm.
at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin; in association with a pharmaceutically acceptable carrier. The composition according to claim 1, wherein the oxidant comprises carbamide peroxide. The composition according to claim 1 or claim 2, which further comprises at least one hydrophilic gelling agent, such as glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol ® polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, or gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1, gdje peroksid je odabran iz grupe koja se sastoji od vodik peroksida pri 3.5% do 6% ukupne kompozicije, karbamid peroksida pri 10% do 16% ukupne kompozicije, i benzoil peroksida pri 2.5% do 5% ukupne kompozicije Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
A propulsive system according to claim 1, wherein said propulsive means are pivot able about an axis being substantially vertical or substantially normal to the surface of said hull (2) at the location of said opening (3) in said hull (2). 
Pogonski sustav prema zahtjevu 1, naznačen time da se navedena pogonska sredstva mogu okretati oko svoje osi koja je u osnovi okomita ili u osnovi pravokutna na navedenu površinu trupa (2) na mjestu navedenog otvora (3) u navedenom trupu (2).
The compounds according to claim 1, characterized in that in formula (I), R1, R2, R4 and R6 are a methyl group, R3 is a hydrogen atom, R5 represents a halogen. 
Spojevi u skladu s patentnim zahtjevom 1, naznačen time što su u formuli (I) R1, R2, R4 i R6 metilne skupine, R3 je atom vodika, a R5 predstavlja halogen.
Improving the levels of those anti-oxidants of the alcohol consumer which specially protect against toxic effects of acetaldehyde. 
- < poboljšanje razine onih anti-oksidanata kod potrošača alkohola koji posebice štite od toksičnog djelovanja acetaldehida, t>&
The method of paragraph 10, wherein the chemotherapy treatment is a taxane. 
Polipeptid za uporabu prema zahtjevu 5, pri čemu je kemoterapijski tretman taksan.
The process according to claim 1 wherein the compound VIII from step h is contacted with a sulfonicacid in an organic solvent and water to afford a salt of VIIIa where Rc is an aryl sulfonic acid 
Postupak prema zahtjevu 1, naznačen time, da se spoj VIII iz koraka (h) dovodi u doticaj sa sulfonskom kiselinom u organskom otapalu i vodi, kako bi se dobila sol od VIIIa gdje R" je arilsulfonska kiselina.
p is 1. A compound of formula (I) according to Claim 3, in free or salt form, 
Spoj formule (1) prema zahtjevu 3, u slobodnom obliku ili u obliku soli, naznačen time, da
A compound of formula (III) wherein R1, R2, R6 and Y are as defined in claim 1 and RA is C1-C6 alkyl or benzyl, with the proviso that the compound is not a compound of formula: wherein R1, R2 and R6 are as defined in claim 1. 
N" *ci R'O,c7" (I) naznačen time što R!, R?, R5 i Y su definirani kao u patentnom zahtjevu 1, a R" je Ci-Cs alkil ili benzil, uz uvjet da spoj nije spoj formule: 1
A method as claimed in claim 1, comprising subjecting the sheet material to a plastic strain of 0.05 or more across at least 65% of the formed area thereof. 
Postupak prema zahtjevu 12 ili zahtjevu 13, naznačen time da se sastoji od podvrgavanja materijala lima (17) plastičnom naprezanju od 0.05 ili više uzduž najmanje 65% njene oblikovane površine.
The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da ima strukturu izabranu iz skupine koja se sastoji od:
a detection chamber (210) allowing the seeds to pass therethrough, said detection chamber having a central axis (211) extending substantially in the same direction as the flow direction of the seeds (102); 
- < komoru (210) za detekciju unutar kućišta (204), navedena komora za detekciju koja omogućava sjemenu da prođe kroz senzor i koja ima središnju os (211) koja se proteže u pravcu kretanja sjemena (102);
The pharmaceutical composition for use of claim 18, wherein the autoimmune disease is selected from the group consisting of lupus, rheumatoid arthritis, and antigen presentation. 
Kristalni spoj prema zahtjevu 8, naznačen time, da je autoimuna bolest odabrana iz skupine koju čine: lupus, reumatoidni artritis i prezentacija antigena.
The dosage form of claim 16, wherein the opioid agonist is selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymorphone, buprenorphine, fentanyl, pharmaceutically acceptable salts thereof, and mixtures of any of the foregoing. 
Farmaceutski oralni dozni oblik prema bilo kojem od zahtjeva 1 do 6, gdje je opioid antagonist odabran iz skupine koja se sastoji od naltreksona, naloksona, nalmefena, ciklazacina, levalorfana, njihovih farmaceutski prihvatljivih soli, ili njihovih smjesa.
or their stereoisomeric and/or tautomeric forms and/or their pharmaceutically acceptable salts. 
ili njihovi stereoizomerni i/ili tautomerni oblici i/ili njihove farmaceutski prihvatljive soli.
The shoulder 31 acts as a stop for the next cup above when cups are stacked. 
Ovo izbočenje 31 djeluje kao graničnik za sljedeću čašu koja dolazi iznad ove kada se čaše slažu jedna u drugu.
Thus the present invention also pertains to a composition comprising a biologically effective amount of a compound of Formula 1, at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, and at least one additional biologically active compound or agent. 
Kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9 1 najmanje jednu dodatnu komponentu izabranu iz grupe koju čine surfaktanti, čvrsti razblaživači 1 tekući razblaživači, pri čemu navedena kompozicija izborno dalje sadrži najmanje jedan dodatno biološki aktivan spoj ili sredstvo.
The compound of claim 1, with the proviso that compounds and or a pharmaceutically acceptable salt thereof are excluded. 
HR P20191348 T1 Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je "S s .
The stable, sterile, injectable composition of claim 14, wherein the hyaluronic acid or salt thereof comprises hyaluronic acid crosslinked with at least one crosslinker selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, and mixtures thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time što se umrežena hijaluronska kiselina iz koraka a) prethodno dobiva iz umrežavanja ne-umrežene hijaluronske kiseline s učinkovitom količinom najmanje jednog sredstva za umrežavanje koje se bira iz skupine koja sadrži 1,4-butandiol diglicidil eter. (BDDE), 1,4-bis(2,3- epoksipropoksi)butan, = 1,4-bisglicidiloksibutan, = 1,2-bis(2,3-epoksipropoksijetilen, - 1-(2,3-epoksipropil)-2,3- epoksicikloheksan, pustrescin, spermidin, spermin, te njihovu smjesu.
A closure of this aspect of the invention may be of generally conventional construction, but for example a suitable construction of a closure part for a vial which may be made from the elastomer material of the invention is described as the “closure part” in applicant's WO-A-04/08317. 
Zatvarač iz ovog izuma može biti općenito konvencionalne izvedbe, ali, na primjer, prikladna izvedba elementa za zatvaranje bočice, koji može biti načinjen od elastomernog materijala iz ovog izuma, opisan je kao "element za zatvaranje" u prijavi WO-A-04/08317. HR P20070541 T3
A preferred embodiment of the present invention is a combination of an M3 antagonist of the invention with a PDE4 inhibitor selected from Cilomilast, Roflumilast, Denbufylline, and Tetomilast. 
Poželjno utjelovljenje predmetnog izuma je kombinacija M3 antagonista sukladno predmetnom izumu s kortikosteroidom odabranim između sljedećeg: budesonid, beklometazon dipropionat, mometazon furoat, ciklesonid i flutikazon propionat.
The extended release dosage form of any one of claims 1 to 28, which is in the form of a tablet formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C or at least about 62 °C for a time period of at least about 1 minute, preferably at least about 5 minutes or at least about 15 minutes. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 23, koji je u obliku tableto napravljene izravnim komprimiranjem sastojka i sušen najmanje podvrgavanjem navedene tablete na temperaturu od barem oko 60% ili od barem oko 62%, u vremenskom razdoblju od barem oko 1 minute, poželjno od barem oko 5 minuta ili od barem oko 15 minuta, .
7, 8 and 9; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising respectively the amino acid sequence SEQ ID Nos. 
1, 2 i 3, laki lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 te sadrži aminokiselinsku sekvenciju SEQ ID No.
The method of claim 2 wherein the neuroleptic agent is selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant. 
Farmaceutski sastav prema zahtjevu 8 za uporabu prema zahtjevu 8 koji nadalje sadrži jedan ili više neuroleptičkih agensa izabranih iz sertindola, olanzapina, risperidona, kvetiapina, aripiprazola, haloperidola, klozapina, ziprasidona i osanetanta.
Method according to claim 15 or 16, wherein said flushing solution comprises a physiological saline solution. 
Postupak u skladu s patentnim zahtjevom 15 ili 16, kod kojega navedena otopina za ispiranje sadržava fiziološku otopinu.
The solid oral extended release pharmaceutical dosage form of claim 1 or 2, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: Oxycodone hydrochloride: 10.0 mg/tablet Lactose (spray-dried): 69.25 mg/tablet 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje koji sadrži 10 mg oksikodon hidroklorida kada je testiran u komparativnoj kliničkoj studiji je bioekvivalentan referentnoj tableti koja sadrži 10 mg oksikodon hidroklorida u formulaciji matrice koja sadrži: a) Oksikodon hidroklorid: 10.0 mg/tableti b) Laktoza (suho raspršena): 69.25 mg/tableti 6) Povidon: 5,0 mg/tableti d) Eudragit" RS 30D (krutine); 10.0 mg/tableti
represents a fluoro atom; 
R5 predstavlja fluorov atom;
The method according to any one of claims 1 to 7, wherein the calcium-based sorbent is selected from the group consisting of calcium carbonate, calcium oxide, calcium hydroxide, calcium magnesium acetate (CaMg2(CH3COO)6), calcium bromide, dolomite (CaCO3●MgO), and combinations thereof. 
Sirovina za gorivo u skladu s patentnim zahtjevom 1, naznačena time, da je sorbens na bazi kalcija odabran iz skupine koju čine kalcijev hidroksid, kalcijev oksid, kalcijev bromid, kalcijev karbonat, dolomit, kalcij magnezijev acetat i njihove kombinacije.
Deposit Name Date of Deposit 
Datum međunarodne objave:
A method for treating a disease or condition mediated by RORgammaT in a subject comprising administering to the subject an amount of a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, that is effective for treating the disease or condition mediated by RORgammaT in the subject, wherein the disease or condition is multiple sclerosis, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis or mucosal leishmaniasis. 
Spoj za uporabu u skladu s patentnim zahtjevom 24, naznačen time što je bolest ili stanje autoimuna bolest ili upalna bolest. Spoj za uporabu u skladu s patentnim zahtjevom 24, naznačen time što je bolest ili stanje multipla skleroza, upalna bolest crijeva, Crohnova bolest, ankilozirajući spondilitis, psorijaza, reumatoidni artritis, astma, osteoartritis, Kawasakijeva bolest, Hashimotov tireoiditis ili leishmanijaza sluznice.
Use of an aqueous solution comprising at least one earth alkali hydrogen carbonate obtained by the process according to any one of claims 1 to 18 for the production of a precipitated earth alkali carbonate and/or hydromagnesite, and in particular for the production of a precipitated calcium carbonate and/or hydromagnesite. 
Uporaba vodene otopine koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat dobiven sa postupkom prema bilo kojem od zahtjeva 1 do 18 naznačena time da je za proizvodnju istaloženog zemnoalkalijskog karbonata i/ili hidromagnezita, te naročito za proizvodnju istaloženog kalcijevog karbonata i/ili hidromagnezita.
The compound according to clause 1, wherein the compound has formula I-B: wherein, independently for each occurrence: 
Spoj prema patentnom zahtjevu 1, pri čemu je spoj formule I-B: o KK Ci H R* O
Method in accordance with claim 20, in which, before insertion in the opening, the block is cement rendered or pre-rendered. 
Metoda prema zahtjevu 20, naznačena time da se prije umetanja u otvor, na blok (1,2) nanosi cementna žbuka ili predžbuka.
Rb is selected from the group consisting of hydrogen, C1-4 alkyl, and aryl C1-4 alkyl R7 is selected from the group consisting of hydrogen, and C1-4 alkyl; 
Rb se bira iz skupine koju čine vodik, C1-4 alkil i aril C1-4 alkil; se bira iz skupine koju čine vodik i C1-4 alkil;
A counter as claimed in claim 19 or 20, wherein said second ring member comprises a plurality of substantially equally-spaced protrusions and wherein said limiting mechanism engages with said protrusions for limiting said free rotation of said second ring member. 
Brojač kao što je navedeno u zahtjevima 16 ili 17, naznačeno time da navedeni drugi prstenasti element (202, 1510) sadrži pluralitet značajno jednako udaljenih izbočenja (1512) i naznačeno time da navedeni mehanizam ograničenja (1506) djeluje s navedenim izbočenjima radi ograničavanja navedene slobodne rotacije navedenog drugog prstenastog elementa.
Preparation of Representative Tablets of the Invention 
Broj objave europskog patenta:
A developer supply container according to claim 1, wherein the drive converting portion converts the rotational force generated by the rotation of the gear portion to the force for operating the pump portion to reciprocate the pump portion. A developer supply container according to claim 1, wherein the drive converting portion converts the rotational force so that an internal pressure of the developer discharging chamber changes between a pressure lower than an ambient pressure and a pressure higher than the ambient pressure. 
Spremnik za nadopunu razvijača (1) sukladno Zahtjevima 1 ili 2, gdje navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da se unutarnji pritisak barem navedene komore za pražnjenje razvijača (3h) mijenja između pritiska nižeg od pritiska okoline i pritiska višeg od pritiska okoline s resiprocitetom navedenog dijela za ubrizgavanje (2b).
is H, aralkyl, or heterocyclyl; m and n are independently an integer from 0 to 1; 
R? jeH, aralkil, ili heterociklil; min su nezavisno cijeli broj od 0 do 1;
M is defined as a metalloid such as tin, boron, sodium, lithium and the like or M can be an activated hydrogen that is lost upon coupling to compounds of formula XII or XI. 
M je definiran kao metaloid kao što su kositar, bor, natrij, litij i slično ili M može biti aktivirani vodik koji je izdvojen nakon spajanja na spojeve formule XII ili XI.
The compound for use of any one of claims 1-4, wherein the compound is formulated for administration 5 days prior to the administration of the antibody. 
Spoj za primjenu prema zahtjevu 1, 3 ili 6, naznačen time što je spoj dalje oblikovan za drugo davanje poslije davanja cjepiva.
A method for producing an IL-23p19 antibody, comprising culturing the isolated host cell of claim 13 under conditions such that the IL-23p19 antibody is expressed and recovered. 
In vitro metoda za proizvodnju najmanje jednog IL-23p19 antitijela, obuhvaćajući prevođenje molekula nukleinske kiseline prema patentnom zahtjevu 3 pod takvim uvjetima da je IL-23p19 antitijelo eksprimirano u detektabilnim ili nadoknadivim količinama.
A substance for cleaning water from oil or oil products or metal ions, consisting of an aqueous solution of an organic polymer, different in the respect that the organic polymer used represents polysaccharide microgels that have a molecular mass of 20,000-200,000 Da and a particle size of 50-600 nm, while the concentration of the microgels in the solution varies from 0.1 to 20 g/l. 
Upotreba vodene otopine polisaharidnih mikrogelova za pročišćavanje vode od lebdećih čestica nafte ili naftnih proizvoda, i opcionalno od metalnih iona, imajući koncentraciju mikrogelova od 0,1 do 20 g/l, naznačeno time da se koristi sposobnost polisaharida da budu adsorbirani na interfaznoj površini u obliku mikrogelova, naznačeno time da mikrogelovi imaju molekularnu masu od 20.000 do 200.000 Da i veličinu čestice od 50 do 600 nm, naznačeno time da je pH vrijednost otopine izmijenjena tako da izazove formiranje aglomerata, sačinjenih od spomenutih lebdećih čestica nafte ili naftnih poizvoda premazanih tankom polisaharidnom opnom.
for compounds of formula I wherein A represents S, cyclisation of a compound of formula IIa, wherein A1 to A5, X, W and D are as defined in Claim 1; 
za spojeve s formulom I pri čemu A predstavlja S, ciklizacijom spoja s formulom IIa, [image] pri čemu A1 do A5, X, W i D su kako je definirano u zahtjevu 1;
The compositions of this invention may be formulated by conventional methods of admixture such as blending, filling, compressing and coating. 
Kompozicije ovog izuma mogu se formulirati konvencionalnim metodama miješanja kao što su stapanje, punjenje, komprimiranje i presvlačenje.
The composition for use according to claim 1 or claim 2, wherein the mRNA encodes an enzyme which is abnormally deficient in an individual with a lysosomal storage disorder. 
Sastav za upotrebu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje mRNA kodira enzim koji je neuobičajeno manjkav kod osobe s poremećajem lizozomske pohrane.
subjecting a compound of the following formula 2 to a Vilsmeier reaction to prepare a compound of the following formula 3; 
podvrgnuti spoj formule 2 Vilsmeierovoj reakciji radi pripreme spoja formule 3;
The reaction can be carried out using methods well known to one skilled in the art, such as for example in presence of a coupling agent such as 1,1′-carbonylbis-1H-imidazole in a solvent such as tetrahydrofuran at a temperature ranging from 20 to 70° C. 
Reakciju se može provesti postupcima dobro poznatim stručnjacima, primjerice u prisutnosti kondenzacijskog sredstva, poput 1,1'-karbonilbis-177-imidazola, u otapalu, poput tetrahidrofurana, na temperaturi u rasponu od 20 do 70 *C.
A magnetic drive (26) for food processing equipment including a food-contact chamber (22, 122), comprising: 
Magnetni pogon za opremu za preradu hrane koji obuhvaća komoru za kontakt s hranom, te magnetni pogon sadrži:
Item 12. The set of panels according to any of the preceding items, wherein the adjacent outer panel edges (17, 18) in a corner portion are inclined inwardly against the main plane (MP) of the panels. 
Komplet dijelova namještaja prema bilo kojem od prethodnih zahtjeva, naznačen time da su susjedmi vanjski rubovi ploče (17, 18) u kutnom dijelu nagnuti prema unutra prema glavnoj ravnini (MP) ploča.
for the preparation of the compounds of the general formula (I) - wherein 
kod dobivanja spojeva opće formule (I), gdje
The compound or pharmacologically acceptable salt thereof according to claim 1, 12, 15 or 16, wherein X1 is -CH=CH-. 
Spoj ili njegova farmakološki prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da X1 je -CH=CH-.
The composition of tested formulations were the following (Table V), noting that the water evaporates during the freeze-drying procedure: 
Sastav testiranih oblika bio je sljedeći (Tablica V), uz napomenu da voda isparava tokom procedure sušenja zamrzavanjem: